RECKITT INVESTS UP TO $600 MILLION TO ACCELERATE U.S.-BASED INNOVATION, EXPAND ACCESS TO HEALTHCARE PRODUCTS, AND STRENGTHEN SUPPLY RESILIENCE

These phased investments aim to fast-track innovation, sharpen responsiveness to evolving consumer needs, and strengthen supply resilience to ensure reliable access to essential healthcare products. Reckitt employs more than 4,000 employees at seven manufacturing sites and three science and innovation centers across the United States.

"With a legacy dating to 1892, Reckitt has maintained a significant presence across the U.S. for more than a century. Our iconic brands including Lysol® and Mucinex® are trusted by millions of American families spanning generations," said Jérôme Lemaire, President, Reckitt North America. "Today's investments will continue building our scientific leadership and R&D, drive new innovations and expand our infrastructure allowing Reckitt to increase access for consumers to high-quality health products."

Reckitt recently relocated its North American campus in New Jersey to support commercial and operational teams. As the next phase of development, the company will break ground on a new state-of-the-art science and innovation center with best-in-class capabilities in disinfection, microbiology, surface care, laundry care and personal care.

This flagship germ protection hub within Reckitt's global R&D network will be pivotal in advancing Reckitt's portfolio, including Lysol. At the center of this transformation is a new model for innovation that brings together world-class R&D, advanced scientific capabilities, and commercial expertise to speed the path from concept to shelf.

"Investing in advanced R&D capability is essential to building for the future," said Angela Naef, Ph.D., Chief R&D Officer, Reckitt. "This investment fundamentally changes how we innovate. By bringing science, insight and execution closer together, we can move faster from discovery to delivery, developing high-quality, science-led solutions that meet evolving consumer needs and scale globally."

Reckitt has doubled its initial investment for its state-of-the art OTC manufacturing facility in North Carolina. The site will become its largest OTC manufacturing facility in the U.S. with additional funding supporting expanded production capacity for Mucinex® tablets and liquids, as well as increased production volumes for Move Free®. The site will open in the first half of 2027. This investment also significantly expands the facility's physical footprint, creating the space needed to support future growth, enhance manufacturing flexibility, and accommodate new capabilities as demand evolves.

On November 19, the company will be hosting its first Reckitt Focus On event in the United States, where Jérôme Lemaire and other U.S. leaders will showcase the North America business. To register your interest in joining us, please use the following link: event.swisscom.ch/v/northamerica. 

About Reckitt

Reckitt is a world-class consumer health and hygiene company on a mission to deliver better health in more hands, every day. Founded in 1840 in the United Kingdom, Reckitt is home to some of the world's most trusted and recognized brands across Germ Protection, Household Care, Intimate Wellness and Self Care, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet.

Operating in more than 80 countries, Reckitt sells approximately 30 million products every day and employs around 36,000 people worldwide. Through trusted brands, science-led innovation and deep consumer understanding, Reckitt helps make health, hygiene and wellbeing more accessible for millions of people while creating sustainable value for consumers, customers, communities and shareholders.

For more information, visit reckitt.com/us.

Reckitt is the trading name of the Reckitt group of companies

Media Contacts

Will Hill
Global Media Director
media&[email protected] 

Jennifer O'Neill
Head of Communications & Corporate Affairs, Americas
[email protected]

SOURCE Reckitt